论文部分内容阅读
目的探讨血清可溶性上皮钙黏蛋白(sE-cadherin/sE-cad)、TPSA的测定在早期诊断前列腺癌中的意义。方法采用酶联免疫吸附测定法(ELISA法)检测42例前列腺癌(Pca)、71例前列腺增生(BPH)患者、20例正常组血清中的sE-cad水平;采用放射免疫法(RIA法)检测42例前列腺癌(Pca)、71例前列腺增生(BPH)患者、20例正常组血清中的TPSA水平。结果 Pca组血清sE-cad水平(12.4860±6.1731)μg/L,明显高于BPH组(6.2275±1.9518)μg/L,正常组(5.6510±1.0303)μg/L(P<0.05);Pca组血清PSA水平(48.1512±26.8345)ng/mL明显高于BPH组(4.3804±5.0627)ng/mL,正常组(0.8241±0.5263)ng/mL(P<0.05);sE-cad、TPSA敏感性、特异性分别为80.95%、90.48%、78.87%和54.93%;且sE-cad(69.39%)阳性预测值高于TPSA(54.29%)。结论血清可溶性上皮钙黏蛋白对前列腺癌的早期诊断具有重要意义,可能成为一种新的肿瘤标志物应用于临床。
Objective To investigate the significance of serum soluble e-cadherin (sE-cad) and TPSA in the early diagnosis of prostate cancer. Methods The serum levels of sE-cadherin in 42 cases of prostate cancer (Pca), 71 cases of benign prostatic hyperplasia (BPH) and 20 cases of normal control group were detected by enzyme linked immunosorbent assay (ELISA). The radioimmunoassay (RIA) TPSA levels were measured in 42 cases of prostate cancer (Pca), 71 cases of benign prostatic hyperplasia (BPH) and 20 cases of normal serum. Results The serum level of sE-cad in Pca group was significantly higher than that in BPH group (12.4860 ± 6.1731 μg / L, 6.2275 ± 1.9518 μg / L, 5.6510 ± 1.0303 μg / L, Pca group PSA level (48.1512 ± 26.8345) ng / mL was significantly higher than BPH group (4.3804 ± 5.0627) ng / mL, normal group (0.8241 ± 0.5263) ng / mL (80.95%, 90.48%, 78.87% and 54.93% respectively). The positive predictive value of sE-cad (69.39%) was higher than that of TPSA (54.29%). Conclusions Serum soluble cadherin is of great importance in the early diagnosis of prostate cancer and may be a new tumor marker for clinical application.